Laman UtamaHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Tutup sebelumnya
€25.85
Julat hari
€25.67 - €25.67
Julat tahun
€19.52 - €36.69
Permodalan pasaran
3.58B USD
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD) | Mac 2024info | Perubahan T/T |
---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 126.19J | 28.63% |
Pendapatan bersih | -125.30J | -357.42% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -1.02 | -326.67% |
EBITDA | -121.67J | -339.34% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(USD) | Mac 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 520.91J | 8.30% |
Jumlah aset | 955.15J | 7.16% |
Jumlah liabiliti | 459.74J | 7.87% |
Jumlah ekuiti | 495.40J | — |
Syer tertunggak | 124.20J | — |
Harga kepada buku | 6.63 | — |
Pulangan pada aset | -39.90% | — |
Pulangan pada modal | -43.18% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(USD) | Mac 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -125.30J | -357.42% |
Tunai daripada operasi | -92.38J | -191.68% |
Tunai daripada pelaburan | -268.94J | -645.70% |
Tunai daripada pembiayaan | 430.78J | 82,741.73% |
Perubahan bersih dalam tunai | 69.49J | 203.27% |
Aliran tunai bebas | -91.82J | -262.49% |
Perihal
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Diasaskan
1 Jan 2004
Ibu pejabat
Tapak web
Pekerja
525